Anthony Elias

15PUBLICATIONS
177CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 16, 2025
A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.

Breelyn A Wilky, Katherine A Julian, Alessandra Maleddu

|Mar 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.

William D Tap, Gregory M Cote, Howard Burris

|Oct 05, 2024
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.

Anthony D Elias, Alyse W Staley, Monica Fornier

|Dec 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.

Kathy S Albain, Christina Yau, Emanuel F Petricoin

|May 20, 2023
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.

Anthony D Elias, Nicole S Spoelstra, Alyse W Staley

|May 19, 2023
Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway.

Michael P Ludwig, Matthew D Galbraith, Neetha Paul Eduthan

Pageof 3

Frequent Collaborators

4 joint publications

Jennifer K Richer

3 joint publications

Rosa I Gallagher

2 joint publications

Tony Philip

2 joint publications

Angela M DeMichele